- Alkermes to Report Second Quarter Financial Results on July 24, 2024
- Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
- Alkermes to Participate in Two Upcoming Investor Conferences
- Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
- Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
- Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
- Alkermes plc Reports First Quarter 2024 Financial Results
More ▼
Key statistics
On Monday, Alkermes Plc (ALKS:NSQ) closed at 24.80, 12.68% above the 52 week low of 22.01 set on Oct 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.82 |
---|---|
High | 25.11 |
Low | 24.48 |
Bid | 22.71 |
Offer | 25.71 |
Previous close | 24.80 |
Average volume | 2.05m |
---|---|
Shares outstanding | 169.22m |
Free float | 167.09m |
P/E (TTM) | 7.03 |
Market cap | 4.16bn USD |
EPS (TTM) | 3.50 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 21:00 BST.
More ▼